GLP-1s for Veterans: VA Coverage, Tricare, and What's Actually Reimbursed

Veterans carry elevated rates of obesity, type 2 diabetes, sleep apnea, and cardiovascular disease — often service-connected or aggravated by service. The VA and Tricare have historically been among the most generous payers for GLP-1 medications, but the policy landscape shifted significantly in 2025 and continues to evolve in 2026.

This guide covers what's actually reimbursable today, the prior authorization paths that work, and the self-pay options when coverage is denied.

VA coverage: what's on the National Formulary

The VA National Formulary is the list of medications available through VA pharmacies. As of 2026, the coverage framework breaks down like this:

The VA's Wegovy criteria, per the most recent Criteria for Use document (revised August 2025), require:¹

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, metabolic syndrome, OSA, osteoarthritis, MASH).
• Failure of prior weight-loss efforts, typically documented lifestyle modification.
• Enrollment in the VA's MOVE! weight management program is often a prerequisite or co-requisite.
• No history of medullary thyroid carcinoma, MEN2, or pancreatitis of unknown cause.

The MASH and MACE pathways

Two VA pathways that are less well-known but increasingly relevant:

• MASH (metabolic dysfunction-associated steatohepatitis): Wegovy was FDA-approved for MASH in August 2025. Veterans with imaging-confirmed fatty liver disease and BMI criteria can qualify under this indication even if the weight-loss pathway has been denied.
• Secondary MACE prevention: Veterans with prior MI, stroke, or symptomatic PAD qualify for Wegovy under the cardiovascular indication — a less-restrictive criterion than pure weight loss.

For veterans with service-connected cardiovascular conditions, the MACE pathway often opens access where the weight-loss pathway would not.

CHAMPVA: narrower than you'd think

CHAMPVA — which covers dependents and survivors of veterans with permanent service-connected disabilities — tightened GLP-1 coverage in 2025. As of January 2025, CHAMPVA covers:²

• Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza — only with type 2 diabetes diagnosis.
• Zepbound — only with moderate-to-severe OSA diagnosis.
• Wegovy — only with MASH or MACE prevention diagnosis.
• No CHAMPVA coverage for any GLP-1 prescribed purely for weight loss.

This represents a substantial narrowing from earlier, more permissive coverage. CHAMPVA beneficiaries pursuing weight loss alone will need self-pay alternatives.

Tricare: plan-specific coverage

Tricare's GLP-1 coverage has evolved through 2025 and 2026. The current framework:³

• Type 2 diabetes: All eligible Tricare beneficiaries get coverage for Trulicity, Ozempic, Mounjaro, and Victoza with prior authorization, regardless of plan.
• Weight loss (Wegovy, Zepbound, and non-GLP-1 alternatives): Covered with prior authorization for Tricare Prime and Tricare Select beneficiaries. As of August 31, 2025, weight-loss medication coverage was eliminated for non-Prime/non-Select beneficiaries — including many Tricare for Life (Medicare-eligible retiree) enrollees.
• Military Treatment Facility (MTF) pharmacies: Lowest or zero cost for active duty; may have availability limitations.
• Retail and mail-order: Available with applicable copays per plan.

The prior authorization typically requires documentation of BMI, at least one qualifying comorbidity, and an attempted lifestyle intervention of at least 3–6 months.

Active-duty considerations

For active-duty service members, GLP-1 use for weight loss carries different considerations than for veterans:

• No automatic disqualification. Taking a prescribed medication for a legitimate medical condition should not negatively affect a military career.
• Body composition standards still apply. GLP-1s can help meet them; they're not a shortcut around annual tape tests or fitness assessments.
• Deployment considerations: Weekly refrigerated injections present logistical challenges in field environments. Many deployed troops switch to oral semaglutide (Rybelsus) or temporarily pause therapy.
• Fitness-for-duty standards: GLP-1 side effects (nausea, fatigue) during dose titration can temporarily affect readiness. Plan titrations around training cycles, not during high-intensity operations or deployments.

Working the VA system: the playbook that actually gets approval

When VA coverage is denied or unavailable

Not all veterans have full VA enrollment, and not all qualifying veterans get GLP-1 approval on the first pass. Options:

• Community Care Network: VA-funded care through non-VA providers, available when VA facilities can't deliver timely care. Check eligibility with your VA.
• Cash-pay telehealth: Compounded semaglutide and tirzepatide through licensed telehealth providers runs $150–$350/month. Not reimbursed by VA but accessible quickly.
• Manufacturer savings programs: Novo Nordisk and Eli Lilly run assistance programs for commercially insured patients; VA/Tricare eligibility varies.
• TrumpRx (2026 program): Direct-to-patient brand-name pricing launched in 2026 for certain medications. Current availability and pricing vary.

Service-connected conditions worth revisiting

Veterans with specific service-connected diagnoses have stronger paths to GLP-1 coverage:

• Type 2 diabetes recognized as presumptive service-connected for certain exposures (Agent Orange, burn pits post-PACT Act).
• Obstructive sleep apnea increasingly recognized as service-connected, particularly secondary to PTSD, tinnitus, or respiratory conditions.
• Cardiovascular disease following service-connected hypertension or diabetes.
• Metabolic syndrome associated with PTSD (medication-related weight gain from psychiatric medications).

If any of these describe you and you're not currently rated or getting benefits, consider filing a claim or asking a Veteran Service Organization (VFW, DAV, American Legion) for help — the GLP-1 approval pathway often follows service-connection recognition.

The bottom line for veterans

The VA remains one of the better payers for GLP-1s in the US, but the coverage pathways require navigation and documentation. Type 2 diabetes, OSA, MASH, and MACE prevention all open doors that pure weight-loss requests don't. MOVE! enrollment strengthens cases. Denials can usually be appealed.

For veterans without full VA enrollment or who don't qualify under current criteria, cash-pay telehealth at $150–$350/month is the practical alternative. For a 9–12 month course, total spending is typically $2,000–$4,000 — a meaningful but achievable investment for a condition that compounds long-term health costs if left untreated.

You served. Use the benefit system as it exists, and use the alternative channels when it falls short.